If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-15

BIONi010-C +dox inducible NGN2-GFP

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Available within next 12 months
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-15
Alternative name(s)
BIONi010-C +dox inducible NGN2-GFP
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
Notes This line contains an NGN2-GFP fusion gene, which is integrated into the AAVS1 locus and inducible by doxycycline. It is isogenic to the line BIONi010-C, which has already been characterized. For stem cell marker expression and differentiation in all three germ layers, please refer to BIONi010-C. No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23

Provider

Depositor Bioneer (BION)
Owner Bioneer (BION)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-15
BioSamples SAMEA104008229
Cellosaurus CVCL_RM87
Wikidata Q54796759

General Information

Publications View all related publications on hPSCreg (2)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium Essential 8
Passage method EDTA
O2 concentration 18
CO2 concentration 5
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 18 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Morphology pictures

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 27
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
NEUROG2 (target)
Gene knock-in
AAVS1 locus
GFP
19q13
DOX inducible NGN2-GFP expression triggers transdifferentiation of iPS cells to GFP positive neurons
TALEN